Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Semiquantification of PFAS in nontarget analysis via ionization efficiency: A critical review of evidence and validation frameworks.

Created on 10 Aug 2026

Authors

Xin Xin, Huijiao Wang, Zhenyu Wang, Yan Wang, Caiyun Zhang, Kaichang Yu, Pin Hou, Huiyu Dong

Published in

Talanta. Volume 312. Issue Pt A. Pages 130411. Aug 06, 2026. Epub Aug 06, 2026.

Abstract

Semiquantitative PFAS estimates can support local screening, but their use across new PFAS structures, sample matrices, or analytical platforms requires direct validation. This need is acute in quantitative nontarget analysis (qNTA), where PFAS diversity far exceeds the availability of authentic and isotopically labelled standards. Ionization-efficiency/response-factor (IE/RF)-based approaches help bridge this standards gap, yet existing reviews have rarely linked validation design to the concentration-use claims it can support. We therefore propose a dimension-aware L0-L4 evidence-to-claim framework that evaluates structural, matrix, and platform transfer independently and records transfer outcome separately from validation scope. We applied the framework to 83 study/workflow settings from 52 articles. Across these settings, 77 supported only local or same-context use (L0), while only six supported matrix and/or platform transfer (L2, L3, or L2+L3); none supported structural transfer (L1) or fully integrated deployment (L4). Even where point performance was reported, empirical coverage, explicit applicability-domain/out-of-domain (AD/OOD) handling, and predefined action rules were rare, limiting confidence in use beyond the tested context. By showing whether the available evidence supports the intended comparison, the framework distinguishes defensible use from cases requiring recalibration and re-evaluation, a narrower claim, or withholding. It thereby makes clear which qNTA results can inform cross-matrix monitoring, interlaboratory comparison, or risk prioritization and which should not.

PMID:
42571755
Bibliographic data and abstract were imported from PubMed on 10 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement